{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:21:05Z","timestamp":1790997665218,"version":"4.1.0"},"reference-count":32,"publisher":"American Chemical Society (ACS)","issue":"32","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004734","name":"Jewish General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013062","name":"G??nome Qu??bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018851","name":"Warren Y. Soper Charitable Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100018851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018765","name":"Fondation De Famille Alvin Segal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibody therapies have transformed cancer treatment by enabling targeted intervention even in advanced disease stages. However, reliable monitoring of circulating therapeutic antibody levels is critical to ensuring efficacy and patient safety. This study investigates the limitations of an electrochemiluminescence immunoassay (ECLIA) in quantifying a therapeutic immunoglobulin G2 (IgG2) antibody, known to undergo conformational changes in vivo. We observed that the ECLIA failed to reflect increasing antibody concentrations in patient plasma, instead producing a plateau effect. This discrepancy was attributed to the ECLIA\u2019s reliance on the intact structural conformation of the antibody, which may be altered during circulation. In contrast, a mass spectrometry (MS)-based approach successfully quantified the accumulating antibody levels over time, independent of conformational state. These findings highlight the need for alternative quantitation strategies in clinical settings, particularly when structural heterogeneity may compromise the ECLIA performance. Mass spectrometry provides a robust and reliable option for monitoring therapeutic antibodies under these conditions.<\/jats:p>","DOI":"10.1021\/acs.analchem.5c07732","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:01:52Z","timestamp":1786111312000},"page":"23440-23449","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming\nElectrochemiluminescence Immunoassay (ECLIA)\nLimitations: Conformation-Independent Quantitation of a Therapeutic\nAntibody by LC\u2013MS\/MS"],"prefix":"10.1021","volume":"98","author":[{"given":"Claudia","family":"Gaither","sequence":"first","affiliation":[{"name":"Universite\u0301 de Montre\u0301al , , , ,","place":["Saint-Hyacinthe, Que\u0301bec, Canada, J2S 2A4"]},{"name":"MRM Proteomics Inc. , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Popp","sequence":"additional","affiliation":[{"name":"MRM Proteomics Inc. , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyumn","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"MRM Proteomics Inc. , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Lemus","sequence":"additional","affiliation":[{"name":"Alethia Biotherapeutics ULC , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Laurin","sequence":"additional","affiliation":[{"name":"Alethia Biotherapeutics ULC , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Filion","sequence":"additional","affiliation":[{"name":"Alethia Biotherapeutics ULC , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H2X 3X8"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-6512","authenticated-orcid":true,"given":"Christoph H.","family":"Borchers","sequence":"additional","affiliation":[{"name":"Jewish General Hospital , , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H3T 1E2"]},{"name":"Jewish General Hospital , , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H3T 1E2"]},{"name":"Lady Davis Institute for Medical Research , , Jewish General, Hospital , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H3T 1E2"]},{"name":"McGill University , , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H4A 3J1"]},{"name":"McGill University , , , ,","place":["Montre\u0301al, Que\u0301bec, Canada, H3A 2B4"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"6","key":"2026081809073361500_cit1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and\nmortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"2026081809073361500_cit2","doi-asserted-by":"publisher","first-page":"2206672","DOI":"10.1080\/07853890.2023.2206672","article-title":"Global burden of tracheal, bronchus,\nand lung cancer attributable to occupational carcinogens in 204 countries\nand territories, from 1990 to 2019: results from the global burden\nof disease study 2019","volume":"55","author":"Zhang","year":"2023","journal-title":"Ann. Med."},{"issue":"3","key":"2026081809073361500_cit3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer\nStatistics\n2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for\n36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"2026081809073361500_cit4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN\nestimates of incidence and mortality worldwide for 36 cancers in 185\ncountries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"2026081809073361500_cit5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements\nand limitations in traditional anti-cancer therapies: a comprehensive\nreview of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discover Oncol."},{"issue":"3","key":"2026081809073361500_cit6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7150\/ijms.3635","article-title":"Cancer and radiation\ntherapy: current advances and future directions","volume":"9","author":"Baskar","year":"2012","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"2026081809073361500_cit7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrclinonc.2014.191","article-title":"The evolution of cancer surgery and\nfuture perspectives","volume":"12","author":"Wyld","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2026081809073361500_cit8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-030-68334-4_4","article-title":"Conventional Cancer Treatment","volume-title":"Advances\nin Cancer Treatment: From Systemic Chemotherapy to Targeted Therapy","author":"Cavalcanti","year":"2021"},{"key":"2026081809073361500_cit9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1201\/9780429026638","volume-title":"Treatment\nof Cancer","author":"Price","year":"2020","edition":"7"},{"key":"2026081809073361500_cit10","doi-asserted-by":"publisher","first-page":"102864","DOI":"10.1016\/j.eclinm.2024.102864","article-title":"Health inequalities\nin cancer care: a literature review\nof pathways to diagnosis in the United Kingdom","volume":"76","author":"Scott","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2026081809073361500_cit11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2022.01.015","article-title":"Time to diagnosis\nand treatment of lung cancer: A systematic\noverview of risk factors, interventions and impact on patient outcomes","volume":"166","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"issue":"1","key":"2026081809073361500_cit12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring\ntreatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduction Targeted Ther."},{"issue":"3","key":"2026081809073361500_cit13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal Antibodies in Cancer Therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"issue":"5","key":"2026081809073361500_cit14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s41048-018-0070-2","article-title":"Targeting\ntumor cells with antibodies\nenhances anti-tumor immunity","volume":"4","author":"Sun","year":"2018","journal-title":"Biophys. Rep."},{"issue":"2","key":"2026081809073361500_cit15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory\nmonoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat.\nRev. Cancer"},{"issue":"2","key":"2026081809073361500_cit16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A Comprehensive\nReview About the Use of Monoclonal Antibodies in Cancer Therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies"},{"issue":"1","key":"2026081809073361500_cit17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.dmpk.2018.11.003","article-title":"Therapeutic\ndrug monitoring of monoclonal antibodies: Applicability based on their\npharmacokinetic properties","volume":"34","author":"Imamura","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"1","key":"2026081809073361500_cit18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4161\/mabs.1.1.7377","article-title":"Practical\nconsiderations for nonclinical\nsafety evaluation of therapeutic monoclonal antibodies","volume":"1","author":"Lynch","year":"2009","journal-title":"mAbs"},{"issue":"12","key":"2026081809073361500_cit19","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic\ndrug monitoring of anticancer drugs part two\u2500 Targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"2026081809073361500_cit20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12936-020-03225-5","article-title":"Comparison\nof ELISA with electro-chemiluminescence\ntechnology for the qualitative and quantitative assessment of serological\nresponses to vaccination","volume":"19","author":"Bolton","year":"2020","journal-title":"Malar. J."},{"issue":"1","key":"2026081809073361500_cit21","doi-asserted-by":"publisher","first-page":"2183816","DOI":"10.1080\/10717544.2023.2183816","article-title":"Quantitative analysis of therapeutic proteins in biological\nfluids: recent advancement in analytical techniques","volume":"30","author":"Song","year":"2023","journal-title":"Drug Deliv."},{"issue":"2","key":"2026081809073361500_cit22","doi-asserted-by":"publisher","first-page":"03000605251315913","DOI":"10.1177\/03000605251315913","article-title":"An overview\nof ELISA: a review and\nupdate on best laboratory practices for quantifying peptides and proteins\nin biological fluids","volume":"53","author":"Aydin","year":"2025","journal-title":"J. Int. Med. Res."},{"issue":"6","key":"2026081809073361500_cit23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0161-5890(90)90068-B","article-title":"The conformation-sensitive\nimmunoassay: a membrane\nbased ELISA system for identifying antibodies sensitive to alterations\nof protein conformation","volume":"27","author":"Pfund","year":"1990","journal-title":"Mol. Immunol."},{"issue":"2","key":"2026081809073361500_cit24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.molimm.2012.12.005","article-title":"IgG2 disulfide isoform conversion\nkinetics","volume":"54","author":"Liu","year":"2013","journal-title":"Mol. Immunol."},{"issue":"23","key":"2026081809073361500_cit25","doi-asserted-by":"publisher","first-page":"16194","DOI":"10.1074\/jbc.M709987200","article-title":"Human IgG2\nantibodies display disulfide-mediated structural isoforms","volume":"283","author":"Wypych","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"10","key":"2026081809073361500_cit26","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1021\/bi5015216","article-title":"Conformational Difference in Human IgG2 Disulfide Isoforms Revealed\nby Hydrogen\/Deuterium Exchange Mass Spectrometry","volume":"54","author":"Zhang","year":"2015","journal-title":"Biochemistry"},{"key":"2026081809073361500_cit27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jmsacl.2022.09.005","article-title":"A distributable LC-MS\/MS method for\nthe measurement\nof serum thyroglobulin","volume":"26","author":"Shi","year":"2022","journal-title":"J. Mass Spectrom. Adv.\nClin. Lab"},{"key":"2026081809073361500_cit28","unstructured":"U.S. Food and Drug Administration.\n          \n          Bioanalytical\nMethod Validation: Guidance\nfor Industry; U.S. Department of Health and\nHuman Services: Silver Spring, MD, 2018."},{"key":"2026081809073361500_cit29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4614-7209-4_4","article-title":"Development\nof MRM-Based Assays for the Absolute Quantitation of Plasma Proteins","volume-title":"The Low Molecular Weight Proteome: Methods and Protocols","author":"Kuzyk","year":"2013"},{"issue":"7","key":"2026081809073361500_cit30","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/bioinformatics\/btq054","article-title":"Skyline: an open\nsource document editor for creating\nand analyzing targeted proteomics experiments","volume":"26","author":"MacLean","year":"2010","journal-title":"Bioinformatics"},{"issue":"10","key":"2026081809073361500_cit31","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1021\/pr100656u","article-title":"A quantitative\nstudy\nof the effects of chaotropic agents, surfactants, and solvents on\nthe digestion efficiency of human plasma proteins by trypsin","volume":"9","author":"Proc","year":"2010","journal-title":"J. Proteome Res."},{"key":"2026081809073361500_cit32","doi-asserted-by":"publisher","first-page":"972161","DOI":"10.3389\/fimmu.2022.972161","article-title":"Conformation-stabilizing ELISA and\ncell-based assays reveal patient subgroups targeting three different\nepitopes of AGO1 antibodies","volume":"13","author":"Moritz","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.analchem.5c07732","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ancham\/article-pdf\/98\/32\/23440\/66458905\/acs.analchem.5c07732.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ancham\/article-pdf\/98\/32\/23440\/66458905\/acs.analchem.5c07732.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:04:38Z","timestamp":1787069078000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ancham\/article\/98\/32\/23440\/5250323\/Overcoming-Electrochemiluminescence-Immunoassay"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":32,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2026,8,7]]},"published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.analchem.5c07732","relation":{},"ISSN":["0003-2700","1520-6882"],"issn-type":[{"value":"0003-2700","type":"print"},{"value":"1520-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}